Watchlist
WGS · GeneDx Holdings Corp.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-08-07 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.
Current thesis
Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the class-action lead-plaintiff deadline. Mean-reversion into an event, not a fresh accelerating leg; the setup does not clear ahead of the print.
Kill line
A weekly close below $52 breaks the June recovery shelf and the rising 50-day near $56.56, reopening the path to the $32.21 May low; a Q2 blended ARR (Aug 3) below ~$3,300 confirms the busted-growth regime.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for WGS —
As of 20 September 2026, the latest FrontierPicks analysis for GeneDx Holdings Corp. (WGS): Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the class-action lead-plaintiff deadline. Mean-reversion into an event, not a fresh accelerating leg; the setup does not clear ahead of the print.
Kill line: A weekly close below $52 breaks the June recovery shelf and the rising 50-day near $56.56, reopening the path to the $32.21 May low; a Q2 blended ARR (Aug 3) below ~$3,300 confirms the busted-growth regime.
Current Thesis
GeneDx's recovery rests on test growth producing sustained profit at stable reimbursement; the next quarterly report must meet its revenue and profit guidance before the shares lose the August recovery reference. The measurable case is Q3 2026 revenue of at least $122 million, adjusted net income of approximately $2 million and blended average reimbursement rate (ARR) holding near $3,250 per test, using management's 2026-08-03 guidance and commentary. A weekly close below $78.08 ends the price-recovery thesis.
Since the 2026-08-30 note, GeneDx has announced a sponsored-testing partnership with Beren Therapeutics on 2026-09-09. Beren funds genome sequencing for eligible children with suspected Niemann-Pick disease type C; the announcement gives no contract value, reimbursement per test or committed testing volume. It establishes another funding channel, but supplies no quantified change to the earnings case. GeneDx announcement
As an inference, the narrative is maturing — the 2026-08-03 earnings repair remains the financial anchor, while the 2026-09-11 close of $85.27 is below the 2026-08-28 close of $86.33 and the 14-day relative strength index (RSI) has declined from 63.1 to 45.7. A weekly close above that August reference accompanied by higher company revenue guidance would overturn this assessment. These observations describe cooling momentum; they do not establish who is trading.
Bullish and bearish views on GeneDx Holdings Corp.
The model's bull view on GeneDx Holdings Corp. (WGS), in brief: Testing demand supports the recovery. GeneDx reported 30,785 exome and genome tests for Q2 2026 on 2026-08-03, up 32% year over year, with associated revenue of $100.3 million, up 17%. The reported volume supports the demand leg, although revenue growth remains slower. Q2… The bear view: Reimbursement recovery remains incomplete. Both cases follow in full.
Bull Case
- Testing demand supports the recovery. GeneDx reported 30,785 exome and genome tests for Q2 2026 on 2026-08-03, up 32% year over year, with associated revenue of $100.3 million, up 17%. The reported volume supports the demand leg, although revenue growth remains slower. Q2 results
- Profitability has a reported foothold. The 2026-08-03 results showed Q2 adjusted net income of $0.4 million and adjusted gross margin of 70%. Management's Q3 guidance of approximately $2 million adjusted net income makes the next report a measurable test of whether that improvement persists. Q2 results
- Sponsored testing broadens payment access. The 2026-09-09 Beren announcement says eligible patients need no insurance because Beren fully sponsors testing. That is evidence of an alternative payment arrangement; its financial contribution remains undisclosed. Partnership release
Bear Case
- Reimbursement recovery remains incomplete. The 2026-08-03 earnings call put Q2 blended ARR near $3,250 per test versus approximately $3,750 in 2025. Sequential stability at that lower level does not establish a return to the earlier reimbursement economics.
- Annual guidance still limits confirmation. On 2026-08-03, GeneDx affirmed FY2026 revenue guidance of $475–490 million. That unchanged range gives no evidence that the Q2 improvement restored the revenue outlook preceding the May reduction. Q2 results
- Financing accompanied the earnings improvement. The 2026-08-03 financing disclosure increased the Blackstone term facility to $150 million and included approximately $5 million of common equity purchased by an affiliate at $61.00 per share. These are disclosed financing transactions; they do not establish subsequent public-market demand.
Setup & Price Structure
The adjusted daily series records a 2026-09-11 close of $85.27, a three-month price increase of 42.3% and a position 49.1% below the trailing annual high of $167.51. RSI was 45.7 on that date. The recovery remains substantial over the longer window, while the latest close has not exceeded the 2026-08-28 reference of $86.33.
The $78.08 close recorded on 2026-08-14 supplies the historical reference for the thesis-break condition. It is a selected research boundary within the August recovery; the available observations do not establish repeated support tests. No current moving-average value is supplied, so distance above a rising average cannot be stated.
Analyst expectations visibly clustered at $90 when Canaccord Genuity raised its target and BTIG reiterated its target on 2026-08-04. Those dated targets are opinions, and their proximity to the September reference close does not prove crowded ownership. Current short-interest, fund-flow and retail-participation measurements are absent; the sample is too small to support a crowding claim. Dated analyst actions
Catalyst Calendar (next 30 days)
- 2026-09-13 through 2026-10-13: No upcoming company event is listed on GeneDx's events page as checked on 2026-09-13. The 2026-09-08 Wells Fargo conference appears under past events and is no longer a pending catalyst. Company calendar
- ~2026-10-26, est.: Q3 2026 results. ChartMill lists this date, while GeneDx's calendar does not confirm it. This later report is the thesis test: the 2026-08-03 guidance specified $122–124 million revenue, 33,200 exome and genome tests and approximately $2 million adjusted net income. Third-party date estimate
What Would Change Our Mind
Loss of the August recovery reference would break the market case: a weekly close below $78.08, the 2026-08-14 historical close, invalidates this recovery thesis. That threshold does not depend on an unverified current moving average.
The operating case fails its stated test if Q3 2026 revenue falls below the $122 million lower end of management's 2026-08-03 guidance, adjusted net income fails to reach approximately $2 million, or blended ARR falls below the approximately $3,250 Q2 level. Meeting those benchmarks before the price condition fires constitutes the published case playing out. The Q2 observation alone is insufficient to establish a durable reimbursement trend.
Correlation Notes
This is a single-name reimbursement and earnings setup; no measured peer or index correlation is available as of 2026-09-13. The 2026-08-03 gap between exome/genome volume growth of 32% and revenue growth of 17% identifies the company-specific economic issue. A sector rally alone cannot establish that reimbursement has improved.
The 2026-09-09 Beren program links GeneDx to a drug developer through sponsored diagnostics. Its announcement does not quantify GeneDx's sensitivity to Beren's development outcomes, so it cannot support a numerical correlation or a separate drug-approval thesis. Partnership terms
Notes
- Blackstone first-lien term facility totals $150.0M at Term SOFR + 4.50% (1.50% floor), secured on substantially all assets, five-year maturity from the 2026-02-27 agreement.
- Securities class action (Hagens Berman) pending; class period 2025-04-16 to 2026-05-04, lead-plaintiff deadline elapsed 2026-08-03, consolidation timing sits with the court.
- The metric that drives this name is blended average reimbursement rate: approximately $3,250 in Q2 2026 versus $3,750 in 2025. Revenue growth guides below volume growth because of it.
- Adjusted and GAAP results diverge: Q2 adjusted net income was $0.4M while the GAAP result remained a loss. The first wire print of adjusted EPS at $(0.28) was corrected to $0.01.
- GUARDIAN newborn genome screening is long-dated optionality; Freedom Capital has described payer reimbursement for it as years away.
- A quiet period runs in the weeks ahead of quarterly reports; Q2 landed 2026-08-03 and Q3 is estimated for early November 2026.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
VREX
Varex Imaging Corporation
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
See also · stocks to watch